

**CHARACTERIZATION OF THE OXIDATION PRODUCTS OF
(-)-EPIGALLOCATECHIN GALLATE, A BIOACTIVE TEA
POLYPHENOL, ON INCUBATION IN NEUTRAL SOLUTION**

Tsutomu Hatano*, Mami Hori, Miwako Kusuda, Takayo Ohyabu, Hideyuki Ito, and Takashi Yoshida

Faculty of Pharmaceutical Sciences, Okayama University, Tsushima, Okayama
700-8530, Japan. E-mail: hatano@pharm.okayama-u.ac.jp

Abstract – (-)-Epigallocatechin gallate (EGCG) (**1**) changes rapidly into various products in neutral solution containing trace amounts of metal ions as catalysts. In addition to theasinensins A (**2**) and D (**3**), (-)-gallocatechin gallate (**4**), and gallic acid, five products were isolated from a reaction mixture resulting from the incubation of **1**. MS and NMR spectroscopic analyses of the products revealed two monomeric [EGCG-MO_x-M1 (**5**) and M2 (**6**)], and three dimeric [EGCG-MO_x-D1 (**7**), D2 (**8**) and D3 (**9**)] structures.

INTRODUCTION


(-)-Epigallocatechin gallate (EGCG) (**1**), the major polyphenol in green tea, has attracted considerable attention because of its various pharmacological properties, including inhibitory effects on tumor promotion,¹ antioxidant effects,² and suppressive effect on the β -lactam resistance of methicillin-resistant *Staphylococcus aureus* (MRSA).³ Its absorption⁴ and metabolic fate⁵ have also been investigated. EGCG is readily oxidized into various products. Dimeric compounds, such as theasinensins A (**2**) and D (**3**), together with theaflavins, are reported to be formed from EGCG in the fermentation of tea leaves.⁶ The oxidation of tea polyphenols by hydrogen peroxide,⁷ peroxy radicals,⁸ polyphenol oxidase, or crude plant extracts^{9,10} causing structural changes in the A and B rings of EGCG has also been studied.

Recently, we reported that EGCG rapidly changes into several products in a neutral solution, even in the absence of reagents or oxidative enzymes.¹¹ Participation of a trace amount of ferric or some metal ions in the solution was suggested. Four products have already been identified: theasinensins A and D (dimers of EGCG), (-)-gallocatechin gallate (C-2 epimer of EGCG), and gallic acid. Of these, theasinensin A (**2**) showed potent suppressive effects on the antibiotic resistance of MRSA.¹¹ Therefore, we further

characterized the remaining unidentified products. This paper deals with the structures of these polyphenolic products of EGCG.

RESULTS AND DISCUSSION

The products were obtained in the following way. EGCG (**1**) was incubated in phosphate buffer and the reaction mixture was acidified with dilute HCl. The solution was then subjected to column chromatography on MCI-gel CHP-20P. The fractions obtained were further purified using preparative HPLC to give five products, in addition to theasinensins A (**2**)⁶ and D (**3**)⁶, (-)-gallocatechin gallate (**4**),¹² and gallic acid. The five products formed in the reaction had dimeric and monomeric structures of the flavan skeleton, as illustrated below, and were tentatively named EGCG-MOx-M1 (**5**) and M2 (**6**) (monomers), and D1 (**7**), D2 (**8**), and D3 (**9**) (dimers).



EGCG-MOx-M1 (**5**) was obtained as a beige-colored amorphous powder. Electrospray ionization (ESI)-MS showed $[M + H]^+$ and $[M + NH_4]^+$ ion peaks at m/z 473 and 490, respectively. These ion peaks and high-resolution (HR)-ESI-MS indicated that the molecular formula was $C_{22}H_{16}O_{12}$. The 1H NMR spectrum of **5** showed the signals of the A-ring [δ 6.112, 6.106 (1H each, d, $J=2.5$ Hz)], C-ring [δ 5.26 (br s, H-2), 5.83 (m, H-3), 2.99 (br d, $J=17.5$ Hz, H-4a), 3.06 (dd, $J=4.5, 17.5$ Hz, H-4b)], and galloyl protons

[δ 6.99 (2H, s)], indicating that these moieties in the structure were unchanged from **1**. In addition to these protons, the spectrum showed two non-equivalent protons on sp_2 carbons { δ 6.70 [1H, t, $J=1.5$ Hz, H-6(B)], 7.43 [1H, d, $J=1.5$ Hz, H-2(B)]}, indicating that a structural change occurred in the B-ring in **1** [the carbons are numbered based on those in **1**, and H-2(B) means H-2 on the B-ring]. Moreover, the ^{13}C NMR spectrum showed signals assignable to the B-ring carbons at δ 109.9 (C-6), 116.9 (C-2), 149.9 (C-5), 155.6 (C-1), 160.6 (C-3), and 166.1 (C-4). The connectivity of these carbons was assigned based on the following NMR spectral data. The ^1H - ^1H COSY spectrum showed long-range couplings of H-2(B) – H-6(B) and H-2(B) – H-2(C). These protons were then correlated with the following carbons on the B-ring in the ^1H - ^{13}C heteronuclear multiple bond correlation (HMBC) spectrum: H-2(C) with C-1(B) (δ 155.6), C-2(B) (δ 116.9) and C-6(B) (δ 109.9); H-2(B) with C-3(B) (δ 160.6) and C-6(B); H-6(B) with C-2(B), C-5(B) (δ 149.9) and C-2(C) (δ 75.9). Only structure (**5**) satisfied these NMR spectral data and the molecular formula for EGCG-MOx-M1 formed from **1**; this structure can be formed by oxidative cleavage between the phenolic hydroxyl groups at C-3 and C-4 on the B-ring of **1**.

EGCG-MOx-M2 (**6**) was obtained as a light-brown amorphous powder. The ESI-MS showed peaks at m/z 377 ($[\text{M} + \text{H}]^+$) and 394 ($[\text{M} + \text{NH}_4]^+$). The molecular formula $\text{C}_{18}\text{H}_{16}\text{O}_9$ suggested by these ion peaks was confirmed with HR-ESI-MS. Although the molecular mass (M_r 376) was much smaller than that of **1** (M_r 458), the ^1H NMR spectrum indicated that the structures of the A-ring [δ 6.05 (2H, br)], C-ring [δ 4.59 (1H, br s, H-2), 5.72 (1H, dt, $J=1.5, 3.5$ Hz, H-3), 2.93 (2H, d, $J=3.5$ Hz, H-4)], and galloyl group in **6** were still unchanged from those in **1**. The spectrum also showed a 3H singlet at δ 2.33 (H-2') attributable to an acetyl residue, and no other protons related to the structure derived from the B-ring were shown. The ^{13}C NMR spectrum indicated the presence of an acetyl group based on the methyl (δ 27.3, C-2') and ketonic (δ 206.2, C-1') carbon signals. The HMBC spectrum of **6** showed the correlations of the proton signals of H-2', H-2(C), H-3(C), and H-4(C) with C-1', indicating the presence of an acetyl group at C-2(C). Therefore, structure (**6**) was assigned to this compound.

EGCG-MOx-D1 (**7**) was obtained as a light-brown amorphous powder. The ESI-MS showed $[\text{M} + \text{H}]^+$, $[\text{M} + \text{NH}_4]^+$, and $[\text{M} + \text{Na}]^+$ ion peaks at m/z 931, 948, and 953, respectively. The molecular formula $\text{C}_{44}\text{H}_{34}\text{O}_{23}$ suggested by these ion peaks was substantiated by HR-ESI-MS. The ^1H NMR spectrum of **7** showed two sets of protons corresponding to those on the A- and C-rings and the galloyl group of **1** [δ 5.89, 6.00 (1H each, d, $J=2.0$ Hz, coupled to each other), 5.94, 5.98 (1H each, d, $J=2.0$ Hz, coupled to each other) (H-6, H-8; A/D-rings); δ 5.26 (1H, br s, H-2), 5.73 (1H, br m, H-3), 2.92 (1H, dd, $J=4.5, 17.0$ Hz, H-4a), 3.15 (1H, br d, $J=17.0$ Hz, H-4b) (C-ring); δ 4.21 (1H, br s, H-2), 5.78 (1H, br m, H-3), 2.79

(1H, dd, $J=4.5, 17.0$ Hz, H-4a), 2.96 (1H, br d, $J=17.0$ Hz, H-4b) (F-ring); δ 7.05, 7.10 (2H each, s, galloyl \times 2)]. These signals suggested that **7** has a dimeric structure related to that of **2** or **3**. By contrast, the structure of the B/E-rings in **7** differed greatly from **2** or **3**; the spectrum showed the signals of one aromatic { δ 6.85 [1H, s, H-6(B)]}, two aliphatic methine { δ 4.64 [H-2(E)], 5.43 [H-3(E)] (1H each, d, $J=6.0$ Hz)} and a pair of isolated methylene { δ 3.78 [H-6a(E)], 3.22 [H-6b(E)] (1H each, d, $J=16.0$ Hz)} protons. The ^1H - ^1H COSY spectrum of **7** showed long-range couplings of H-2(C) – H-6(B) and H-2(F) – H-2(E), distinguishing the C-ring and F-ring protons. The H-2(E) signal was further coupled with the H-3(E) signal. The E ring of **7** showed the carbon signals of one methylene (δ 36.4, C-6), two methine (δ 49.0, C-2; δ 77.2, C-2), one oxygen-bearing quaternary (δ 89.3, C-1), and two carboxyl (or ester carbonyl) (δ 170.2, C-1; δ 170.4, C-5) functions in the ^{13}C NMR spectrum. The HMBC spectrum showed that H-3(E) is correlated with C-5(E), in addition to the correlations with C-1(E), C-2(E), C-4(E), and C-2(B). Therefore, the C-5(E) carboxyl function is lactonized with the oxygen at C-3(E). The molecular formula and downfield shift of C-3(B) (δ 148.0) (relative to the corresponding carbon of **2**, δ 145.9) suggested the formation of an ether linkage at C-3(B) with C-1(E). The participation of C-3(B) and C-1(E) in the ether linkage was substantiated by the deuterium-induced differential-isotope shift (DIS)^{13,14} spectrum. The C-3(B) signal, along with the C-1(E) signal, showed negligible DIS within 0.05 ppm, while the DIS values for C-4(B) and C-5(B) were 0.16 and 0.18 ppm, respectively. Based on these data, the connectivity of the plain structure of this compound was assigned that shown in formula (**7**).

A compound that is probably identical to **7** was also isolated by another group,^{10,15} and the stereostructure including the configuration at C-3(E) was presented.¹⁰ Therefore we investigated the stereostructure further by measuring the rotating-frame Overhauser-effect spectroscopy (ROESY) on an INOVA AS600 instrument. The ROESY spectrum showed the following correlations concerning the E-ring protons: H-3(E) with H-8(A/D), H-3(C), H-2(C), H-2(E), and H-6a(E); H-2(E) with H-8(D/A), H-3(E), H-2(C), and H-2(F); H-6a(E) with H-3(F) and H-3(E); H-6b(E) with H-3(F). Although it is difficult to postulate a single conformation that satisfies all of these ROE correlations, the correlations H-2(E) – H-3(E) – H-6a(E) and the absence of ROE between H-6b(E) and H-3(E) suggested that the H-3(E) proton is *cis* to H-2(E) on the 6-membered ring. The ROE correlations H-2(C) – H-2(E) – H-2(F) suggested that the stereochemistry at C-2(E) is assignable to that shown in formula (**7**) (see also Figure 1), if the compound is assumed to be produced *via* **2**. In fact, the amount of **2** in the product mixture exceeded that of **3**.




Figure 1. A plausible conformation of **7**

EGCG-MOx-D2 (**8**) was obtained as a light-brown amorphous powder. The ESI-MS measurements using the positive- and negative-ion modes led to the molecular formula $C_{44}H_{34}O_{24}$, based on the molecular ion species at m/z 947 ($[M + H]^+$) and 945 ($[M - H]^-$). Since the 1H and ^{13}C NMR spectra of **8** were similar to those of **7**, except for some differences in the signals of the E-ring protons and carbons, this compound might have a structure in which an additional oxygen is inserted into the E-ring in the molecule of **7**. The 1H NMR spectrum of **8** showed three protons at δ 4.69 (1H, very broad, H-2), 3.73 (1H, d, $J=16.0$ Hz, H-6a), and 3.2 (1H, which overlapped the water signal, H-6b) for the E-ring structure. The broad H-2(E) signal became relatively sharp when the spectrum was measured at an elevated temperature (40 °C). The E-ring carbons were observed as the signals of one methylene (δ 52.2, C-6), one methine (δ 36.8, C-2), one oxygen-bearing quaternary (δ 89.6, C-1), one hemi-ketal (δ 102.8, C-3), and two carboxyl (or ester carbonyl) (δ 170.6, C-4; δ 171.8, C-5) carbons. The broadening of the H-2(E) signal is explainable if slow trans-esterification (lactonization) is assumed at the hydrated keto-function of C-3(E). ROEs were observed for H-2(C) – H-2(E) – H-2(F). Based on these data, structure (**8**), in which an additional oxygen was inserted at C-3, was assigned to EGCG-MOx-D2.

EGCG-MOx-D3 (**9**) was obtained as a light-brown amorphous powder. The ESI-MS spectral analysis indicated its molecular formula was $C_{43}H_{34}O_{23}$, based on the ion peak at m/z 936 ($[M + NH_4]^+$). The molecular mass of **9** was 28 mass units smaller than that of **8**, which corresponds to the loss of CO from **8**, and the result of the HR-ESI-MS analysis substantiated this. The 1H and ^{13}C NMR spectra of **9** indicated that the structural difference distinguishing it from **8** is in part E, which consists of one methylene [δ_C 37.1 (C-6), δ_H 3.40 (2H, br s)], one methine [δ_C 53.7 (C-2), δ_H 4.77 (1H, s)], one oxygen-bearing quaternary [δ_C 90.7 (C-1)], and two carboxyl (or ester carbonyl) [δ_C 172.1 (C-5) and 172.9 (C-3)] carbons. The connectivity of these carbons was indicated by the following correlations in the HMBC spectrum: H-2(F) to C-1(E) and C-2(E); H-2(E) to C-1(B), C-2(B), C-3(B), C-1(E), C-3(E), C-6(E), and C-2(F); H-6(E) to C-1(E), C-2(E), C-5(E), and C-2(F). The molecular formula and the ^{13}C chemical shifts of C-1(E) and C-3(B), which were similar to those of the corresponding carbons in **7**, necessitate the formation of the ether linkage between these two carbons. Based on these data, we assigned structure **9** for EGCG-MOx-D3. The stereostructure at C-2(E) shown in the formula was based on the ROE correlations H-2(C) – H-2(E) – H-2(F).

This study showed that incubating **1** in neutral buffer results in metal-catalyzed oxidation to give dimeric products (**2**, **3**, **7**, **8**, and **9**) and products via oxidative opening of the B-ring (**5**, **6**, **7**, **8**, and **9**). This finding should be considered in any *in vitro* or *in vivo* biological evaluation of EGCG or tea extracts under physiological conditions, since one of the products was a potent suppressor of the

antibiotic-resistance of MRSA.¹¹

EXPERIMENTAL

The NMR spectra were measured on a Varian VXR-500 (500 MHz for ¹H and 126 MHz for ¹³C NMR) and INOVA AS600 NMR (600 MHz for ¹H and 151 MHz for ¹³C NMR) instruments. The solvent used was acetone-*d*₆ containing *ca.* 4% D₂O. The chemical shifts were given in δ (ppm) based on those of the solvent signals (δ_H 2.04; δ_C 29.8). ESI-MS spectral measurement was performed on a Micromass Autospec OA-ToF instrument, and the solvent used was 50% MeOH aq. containing 0.1% ammonium acetate. HPLC was conducted on YMC A302 (analytical) and 324 (preparative) columns using combinations of a 1:1 mixture of H₃PO₄ aq. – KH₂PO₄ aq. and acetonitrile as solvents.

Isolation of the polyphenolic products from 1

Compound (**1**) was treated as reported elsewhere,¹¹ and the products were separated by column chromatography on MCI gel CHP-20P (H₂O-MeOH) or on Sephadex LH-20 (EtOH), and the fractions were further purified using preparative HPLC, to give **5-9** (Yield: **5**, 2.8 mg; **6**, 4.4 mg; **7**, 3.2 mg; **8**, 5.3 mg; **9**, 5.2 mg from 1g of **1**).

EGCG-MOx-M1 (5). [α]_D -116° (*c* 0.25, MeOH). UV λ_{max} (MeOH): 277 nm (log ε 4.06). HR-ESI-MS: *m/z* 490.0967 [M + NH₄]⁺ (Calcd for C₂₂H₁₆O₁₂ + NH₄, 490.0986). ¹H NMR, see text. ¹³C NMR: δ 26.2 [C-4(C)], 67.2 [C-3(C)], 75.9 [C-2(C)], 95.8, 97.1 [C-6(A), C-8(A)], 98.6 [C-10(A)], 109.9 [C-6(B), C-2(G), C-6(G)], 116.9 [C-2(B)], 121.0 [C-1(G)], 139.1 [C-4(G)], 146.0 [C-3(G), C-5(G)], 149.9 [C-5(B)], 155.4, 157.5, 158.0 [C-5(A), C-7(A), C-9(A)], 155.6 [C-1(B)], 160.6 [C-3(B)], 165.9 [C-7(G)], 166.1 [C-4(B)]. The assignments labeled (A), (B), and (C) mean the carbon numbers on the A, B and C-rings, respectively, and (G) means the galloyl group.

EGCG-MOx-M2 (6). [α]_D -40° (*c* 0.43, MeOH). UV λ_{max} (MeOH): 278 nm (log ε 4.10). HR-ESI-MS: *m/z* 394.1139 [M + NH₄]⁺ (Calcd for C₁₈H₁₆O₉ + NH₄, 394.1138). ¹H NMR, see text. ¹³C NMR: δ 25.8 [C-4(C)], 27.3 (C-2'), 67.6 [C-3(C)], 81.2 [C-2(C)], 95.6 [C-6(A)], 96.8 [C-8(A)], 98.5 [C-10(A)], 109.7 [C-2(G), C-6(G)], 121.1 [C-1(G)], 139.0 [C-4(G)], 146.0 [C-3(G), C-5(G)], 155.3 [C-9(A)], 157.4 [C-7(A)], 157.9 [C-5(A)], 166.0 [C-7(G)], 206.2 (C-1').

EGCG-MOx-D1 (7). [α]_D -33° (*c* 0.34, MeOH). UV λ_{max} (MeOH): 276 nm (log ε 4.33). HR-ESI-MS: *m/z* 931.1592 [M + H]⁺ (Calcd for C₄₄H₃₄O₂₃ + H, 931.1569). ¹H NMR, see text. ¹³C NMR: δ 26.6 [C-4(F)], 26.9 [C-4(C)], 36.4 [C-6(E)], 49.0 [C-2(E)], 65.5 [C-3(F)], 68.7 [C-3(C)], 75.6 [C-2(C)], 77.2

[C-3(E)], 77.7 [C-2(F)], 89.3 [C-1(E)], 95.3, 95.4, 96.4, 96.9 [C-6(A), C-6(D), C-8(A), C-8(D)], 98.5 [C-10(D)], 98.9 [C-10(A)], 109.8 [C-6(B)], 109.9 (4C) [C-2(G) × 2, C-6(G) × 2], 114.6 [C-2(B)], 120.9, 121.4 [C-1(G) × 2], 128.2 [C-1(B)], 130.1 [C-4(B)], 138.9, 139.3 [C-4(G) × 2], 145.9 (2C), 146.1 (2C) [C-3(G) × 2, C-5(G) × 2], 147.7 [C-5(B)], 148.0 [C-3(B)], 155.8, 157.0 [C-5(A), C-5(D)], 157.4-157.5 (4C) [C-7(A), C-7(D), C-9(A), C-9(D)], 166.2, 166.7 [C-7(G) × 2], 170.2 [C-4(E)], 170.4 [C-5(E)].

EGCG-MOx-D2 (8). $[\alpha]_D -117^\circ$ (*c* 0.26, MeOH). UV λ_{\max} (MeOH): 275 nm (log ϵ 4.18). HR-ESI-MS: *m/z* 969.1542 [M + Na]⁺ (Calcd for C₄₄H₃₄O₂₄ + Na, 969.1338). ¹H NMR: δ 2.74 [1H, dd, *J*=4.0, 17.5 Hz, H-4b(F)], 2.89 [1H, br d, *J*=17.5 Hz, H-4b(C)], 2.99 [1H, br d, *J*=17.0 Hz, H-4a(F)], 3.2 [overlapped the HDO signal, H-4a(C), H-6b(E)], 3.70 [1H, d, *J*=16.0 Hz, H-6a(E)], 4.19 [1H, br s, H-2(F)], 4.69 [1H, very broad, H-2(E)], 5.40 [1H, br s, H-2(C)], 5.63 [1H, m, H-3(C)], 5.74 [1H, m, H-3(F)], 5.89, 5.93, 5.95, 5.96 [each d, *J*=2.0 Hz, H-6(A), H-6(D), H-8(A), H-8(D)], 6.87 [1H, s, H-6(B)], 7.11, 7.16 [2H each, s, H-2(G) × 2, H-6(G) × 2]. ¹³C NMR: δ 26.9 (2C) [C-4(C), C-4(F)], 36.8 [C-6(E)], 52.2 [C-2(E)], 65.8 [C-3(F)], 69.8 [C-3(C)], 75.4 [C-2(C)], 79.2 [C-2(F)], 89.6 [C-1(E)], 95.8, 95.9, 96.6, 96.9 [C-6(A), C-6(D), C-8(A), C-8(D)], 98.6 [C-10(D)], 99.4 [C-10(A)], 102.8 [C-3(E)], 109.8 [C-6(B)], 110.1 (4C) [C-2(G) × 2, C-6(G) × 2], 116.8 [C-2(B)], 121.3, 122.2 [C-1(G) × 2], 128.5 [C-1(B)], 129.8 [C-4(B)], 138.9, 139.1 [C-4(G) × 2], 145.9 (2C), 146.1 (2C) [C-3(G) × 2, C-5(G) × 2], 147.2 [C-5(B)], 148.6 [C-3(B)], 156.1, 157.3-157.6 (5C) [C-5(A), C-5(D), C-7(A), C-7(D), C-9(A), C-9(D)], 166.4, 166.9 [C-7(G) × 2], 170.6 [C-4(E)], 171.8 [C-5(E)].

EGCG-MOx-D3 (9). $[\alpha]_D -117^\circ$ (*c* 0.26, MeOH). UV λ_{\max} (MeOH): 275 nm (log ϵ 4.18). HR-ESI-MS: *m/z* 969.1542 [M + Na]⁺ (Calcd for C₄₄H₃₄O₂₃ + Na, 969.1338). ¹H NMR: δ 2.68 [1H, dd, *J*=4.0, 17.5 Hz, H-4b(F)], 2.85 [1H, dd, *J*=4.0, 17.5 Hz, H-4b(C)], 2.89 [1H, br d, *J*=17.5 Hz, H-4a(F)], 2.92 [1H, br d, *J*=17.5 Hz, H-4a(C)], 3.40 [2H, br s, H-6(E)], 4.41 [1H, br s, H-2(F)], 4.77 [1H, s, H-2(E)], 5.15 [1H, br s, H-2(C)], 5.40 [1H, m, H-3(C)], 5.75 [1H, m, H-3(F)], 5.87 (1H), 5.95 (2H), 5.99 (1H) [each d, *J*=2.0 Hz, H-6(A), H-6(D), H-8(A), H-8(D)], 6.82 [1H, s, H-6(B)], 7.062, 7.064 [2H each, s, H-2(G) × 2, H-6(G) × 2]. ¹³C NMR: δ 27.0 [C-4(C)], 27.6 [C-4(F)], 37.1 [C-6(E)], 53.7 [C-2(E)], 65.1 [C-3(F)], 68.5 [C-3(C)], 75.6 [C-2(F)], 79.4 [C-2(C)], 90.7 [C-1(E)], 95.48, 95.50, 96.4, 96.6 [C-6(A), C-6(D), C-8(A), C-8(D)], 98.6 (2C) [C-10(A), C-10(D)], 108.9 [C-6(B)], 109.9 (2C), 110.2 (2C) [C-2(G) × 2, C-6(G) × 2], 117.0 [C-2(B)], 121.36, 121.40 [C-1(G) × 2], 126.6 [C-1(B)], 129.9 [C-4(B)], 138.88, 138.91 [C-4(G) × 2], 145.7 (2C), 145.8 (2C) [C-3(G) × 2, C-5(G) × 2], 147.2 [C-5(B)], 147.3 [C-3(B)], 156.3, 157.0 [C-5(A), C-5(D)], 157.3-157.4 (4C) [C-7(A), C-7(D), C-9(A), C-9(D)], 166.5, 166.6 [C-7(G) × 2], 172.1 [C-5(E)], 172.9 [C-3(E)].

DIS measurements.^{13,14} Sample solutions dissolved in acetone-*d*₆ + D₂O (1:3) and acetone-*d*₆ + H₂O (1:3) were put in the outer (5 mm o. d.) and inner (3 mm o. d.) NMR tubes, and the ¹³C NMR spectrum was recorded.

ACKNOWLEDGMENTS

The Varian VXR-500 and INOVA AS600 NMR instruments used in this study are the property of the SC NMR laboratory of Okayama University.

REFERENCES AND NOTES

1. S. Yoshizawa, T. Horiuchi, H. Fujiki, T. Yoshida, T. Okuda, and T. Sugimura, *Phytotherapy Res.*, 1987, **1**, 44.
2. T. Okuda, Y. Kimura, T. Yoshida, T. Hatano, H. Okuda, and S. Arichi, *Chem. Pharm. Bull.*, 1983, **31**, 1625.
3. S. Shiota, M. Shimizu, T. Mizushima, H. Ito, T. Hatano, T. Yoshida, and T. Tsuchiya, *Biol. Pharm. Bull.*, 1999, **22**, 1388.
4. T. Unno, K. Kondo, H. Itakura, and T. Takeo, *Biosci. Biotech. Biochem.*, 1996, **60**, 2066.
5. I. Tomita, M. Sano, K. Sasaki, and T. Miyase, 'ACS Symposium Series. 701. Functional Foods for Disease Prevention. I. Fruits, Vegetables, and Teas', ed. by T. Shibamoto, J. Terao, and T. Osawa, American Chemical Society, Washington, DC, 1998, pp. 209-216.
6. F. Hashimoto, G. Nonaka, and I. Nishioka, *Chem. Pharm. Bull.*, 1992, **40**, 1383.
7. N. Zhu, T.-C. Huang, Y. Yu, E. J. LaVoie, C. S. Yang, and C.-T. Ho, *J. Agric. Food Chem.*, 2000, **48**, 979.
8. S. Valcic, J. A. Burr, B. N. Timmermann, and D. C. Liebler, *Chem. Res. Toxicol.*, 2000, **13**, 801.
9. T. Tanaka, K. Inoue, Y. Betsumiya, C. Mine, and I. Kouno, *J. Agric. Food Chem.*, 2001, **49**, 5785.
10. T. Tanaka, S. Watarumi, Y. Matsuo, M. Kamei, and I. Kouno, *Tetrahedron*, 2003, **59**, 7939.
11. T. Hatano, M. Kusuda, M. Hori, S. Shiota, T. Tsuchiya, and T. Yoshida, *Planta Med.*, 2003, **69**, 984.
12. C. K. Wilkins, J. de Bruijin, O. Korver, D. J. Frost, and K. Weinges, *J. Sci. Food Agric.* 1971, **22**, 480.
13. P. E. Pfeffer, K. M. Valentine, and F. W. Parrish, *J. Amer. Chem. Soc.*, 1979, **101**, 1265.
14. T. Okuda, T. Yoshida, and T. Hatano, *J. Chem. Soc., Perkin Trans. 1*, 1982, 9.
15. We reported the isolation of this compound and the structure except for the configuration at C-3(E) in a preliminary way: M. Hori, T. Kunihiro, T. Hatano, and T. Yoshida, Abstract Papers, 48th Annual Meeting of the Japanese Society of Pharmacognosy (Kanazawa), September 2001, p. 47.